CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013–2017

Neuro-Oncology - Tập 22 Số Supplement_1 - Trang iv1-iv96 - 2020
Quinn T. Ostrom1,2, Nirav Patil1,3,4,5, Gino Cioffi1,3,4, Kristin Waite1,3,4, Carol Kruchko1, Jill S. Barnholtz‐Sloan6,1,3,4,5
1Central Brain Tumor Registry of the United States, Hinsdale, Illinois, USA
2Department of Medicine, Section of Epidemiology and Population Sciences, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas, USA
3Cleveland Center for Health Outcomes Research, Cleveland, Ohio, USA
4Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA
5University Hospitals Health System, Research and Education Institute
6Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA

Tóm tắt

Abstract The Central Brain Tumor Registry of the United States (CBTRUS), in collaboration with the Centers for Disease Control (CDC) and National Cancer Institute (NCI), is the largest population-based registry focused exclusively on primary brain and other central nervous system (CNS) tumors in the United States (US) and represents the entire US population. This report contains the most up-to-date population-based data on primary brain tumors (malignant and non-malignant) and supersedes all previous CBTRUS reports in terms of completeness and accuracy. All rates (incidence and mortality) are age-adjusted using the 2000 US standard population and presented per 100,000 population. The average annual age-adjusted incidence rate (AAAIR) of all malignant and non-malignant brain and other CNS tumors was 23.79 (Malignant AAAIR=7.08, non-Malignant AAAIR=16.71). This rate was higher in females compared to males (26.31 versus 21.09), Blacks compared to Whites (23.88 versus 23.83), and non-Hispanics compared to Hispanics (24.23 versus 21.48). The most commonly occurring malignant brain and other CNS tumor was glioblastoma (14.5% of all tumors), and the most common non-malignant tumor was meningioma (38.3% of all tumors). Glioblastoma was more common in males, and meningioma was more common in females. In children and adolescents (age 0-19 years), the incidence rate of all primary brain and other CNS tumors was 6.14. An estimated 83,830 new cases of malignant and non-malignant brain and other CNS tumors are expected to be diagnosed in the US in 2020 (24,970 malignant and 58,860 non-malignant). There were 81,246 deaths attributed to malignant brain and other CNS tumors between 2013 and 2017. This represents an average annual mortality rate of 4.42. The 5-year relative survival rate following diagnosis of a malignant brain and other CNS tumor was 23.5% and for a non-malignant brain and other CNS tumor was 82.4%.

Từ khóa


Tài liệu tham khảo

Kruchko, 2018, The CBTRUS story: providing accurate population-based statistics on brain and other central nervous system tumors for everyone, Neuro. Oncol., 20, 295, 10.1093/neuonc/noy006

Louis, 2007, WHO Classification of Tumours of the Central Nervous System

Ostrom, 2014, CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011, Neuro. Oncol., 16, iv1, 10.1093/neuonc/nou223

Centers for Disease Control and Prevention (CDC), 1999

Wiśniewski, 2009, Universal sample preparation method for proteome analysis, Nature methods., 6, 359, 10.1038/nmeth.1322

2002

National Cancer Institute

Walker, 2019, Malignant primary brain and other central nervous system tumors diagnosed in Canada from 2009 to 2013, Neuro. Oncol., 21, 360, 10.1093/neuonc/noy195

Wohrer, 2009, The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry, Journal of neuro-oncology, 95, 401, 10.1007/s11060-009-9938-9

Asklund, 2015, Brain tumors in Sweden: data from a population-based registry 1999-2012, Acta oncologica, 54, 377, 10.3109/0284186X.2014.975369

Centers for Disease Control and Prevention National Center for Health Statistics, 2020, National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database: U.S. Cancer Statistics Incidence Analytic Database – 2001-2017

Fritz, 2000, International Classification of Diseases for Oncology

Surveillance Epidemiology and End Results (SEER) Program., 2019

Standards for Cancer Registries Volume III: Standards for Completeness, Quality, Analysis, Management, Security and Confidentiality of Data, 2008

Bray, 2017, Data Comparability and Quality, Cancer Incidence in Five Continents, Vol. XI (electronic version)

McCarthy, 2002, Consensus Conference on Brain Tumor Definition for registration. November 10, 2000, Neuro. Oncol., 134

Surveillance Research Program - National Cancer Institute, 2008

Steliarova-Foucher, 2005, International Classification of Childhood Cancer, third edition, Cancer., 103, 1457, 10.1002/cncr.20910

Swerdlow, 2007, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues

Kleihues, 2000, Tumours of the nervous system: World Health Organization classification of tumours

Louis, 2016, WHO Classification of Tumours of the Central Nervous System

American Joint Committee on Cancer, 2020

Ostrom, 2016, Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004-2012, varying), J Neurooncol, 130, 31, 10.1007/s11060-016-2217-7

Lym, 2015, Completeness and concordancy of WHO grade assignment for brain and central nervous system tumors in the United States, 2004-2011, J. Neurooncol., 10.1007/s11060-015-1775-4

Surveillance Research Program - National Cancer Institute., 2019

R Core Team, 2020

Surveillance Epidemiology and End Results (SEER) Program, 2020

Luo, 2012

Gohel, 2020

Gohel, 2020

Hočevar, 2016, Computation of Graphlet Orbits for Nodes and Edges in Sparse Graphs, 2016, 71, 24

Wickham, 2019, Welcome to the Tidyverse, Journal of Open Source Software, 4, 1686, 10.21105/joss.01686

Sievert, 2020

Xie, 2020

Walker, 2020

Kassambara, 2020

Pebesma, 2018, Simple Features for R: Standardized Support for Spatial Vector Data, The R Journal, 10, 439, 10.32614/RJ-2018-009

NAACCR Race and Ethnicity Work Group, 2012

United States Department of Agriculture, 2013

Surveillance Epidemiology and End Results (SEER) Program

Tiwari, 2006, Efficient interval estimation for age-adjusted cancer rates, Stat. Methods Med. Res., 547

Fay, 2006, Estimating average annual percent change for disease rates without assuming constant change, Biometrics., 62, 847, 10.1111/j.1541-0420.2006.00528.x

2020

Kim, 2000, Permutation tests for joinpoint regression with applications to cancer rates, Stat. Med., 19, 335, 10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z

Zhu, 2012, Predicting US- and state-level cancer counts for the current calendar year: Part II: evaluation of spatiotemporal projection methods for incidence, Cancer., 118, 1100, 10.1002/cncr.27405

Chu, 1994, A method for partitioning cancer mortality trends by factors associated with diagnosis: an application to female breast cancer, J. Clin. Epidemiol., 47, 1451, 10.1016/0895-4356(94)90089-2

Surveillance Epidemiology and End Results (SEER) Program, 2020, SEER*Stat Database: Incidence - SEER Research Data, 9 Registries, Nov 2019 Sub (1975-2017) - Linked To County Attributes - Time Dependent (1990-2017) Income/Rurality, 1969-2017 Counties

Louis, 2016, The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary, Acta Neuropathol., 131, 803, 10.1007/s00401-016-1545-1

Ferlay, Histological groups., Cancer Incidence in Five Continents Volume XI2019

Surveillance Epidemiology and End Results (SEER) Program

Ostrom, 2020, Pilocytic astrocytomas: where do they belong in cancer reporting?, Neuro. Oncol., 22, 298

Edwards, 2014, Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer, Cancer, 120, 1290, 10.1002/cncr.28509

Zullig, 2012, Cancer incidence among patients of the U.S. Veterans Affairs Health Care System, Mil. Med., 177, 693, 10.7205/MILMED-D-11-00434

Clegg, 2002, Impact of reporting delay and reporting error on cancer incidence rates and trends, J. Natl. Cancer Inst, 1537

Midthune, 2005, Modeling Reporting Delays and Reporting Corrections in Cancer Registry Data, Journal of the American Statistical Association, 100, 61, 10.1198/016214504000001899

Surveillance Epidemiology and End Results (SEER) Program, 2020

Li, 2016, Are Benign and Borderline Brain Tumors Underreported?, J Registry Manag., 43, 187

Anderson, 1998, Report of the Second Workshop on Age Adjustment, Vital Health Stat. 4., I-vi, 1

Anderson, 1998, Age standardization of death rates: implementation of the year 2000 standard, Natl. Vital Stat. Rep., 47, 1

L., 2018

Johnson, 2007, The 2007 Multiple Primary and Histology Coding Rules

Ostrom, 2018, Females have the survival advantage in glioblastoma, Neuro. Oncol., 20, 576, 10.1093/neuonc/noy002

Ostrom, 2018, Adult Glioma Incidence and Survival by Race or Ethnicity in the United States From 2000 to 2014, JAMA Oncol, 4, 1254, 10.1001/jamaoncol.2018.1789

Siegel, 2019, Cancer statistics, 2019, CA Cancer J Clin., 69, 7, 10.3322/caac.21551

Zhang, 2016, Complete prevalence of malignant primary brain tumors registry data in the United States compared with other common cancers, 2010, Neuro. Oncol., 10.1093/neuonc/now252

Gittleman, 2018, Survivorship in Adults with Malignant Brain and other Central Nervous System Tumor from 2000-2014, Neuro. Oncol., 10.1093/neuonc/noy090

2012, DevCan: Probability of Developing or Dying of Cancer Software, Version 6.7.7 Surveillance Research Program, Statistical Methodology and Applications

Fay, 2003, Age-conditional probabilities of developing cancer, Stat. Med., 22, 1837, 10.1002/sim.1428

Fay, 2004, Estimating age conditional probability of developing disease from surveillance data, Population health metrics., 2, 6, 10.1186/1478-7954-2-6

Surveillance Epidemiology and End Results (SEER) Program, DevCan database: “SEER 18 Incidence and Mortality, 2000-2016, with Kaposi Sarcoma and Mesothelioma”

Braganza, 2012, Ionizing radiation and the risk of brain and central nervous system tumors: a systematic review, Neuro. Oncol., 14, 1316, 10.1093/neuonc/nos208

Amirian, 2016, Approaching a Scientific Consensus on the Association between Allergies and Glioma Risk: A Report from the Glioma International Case-Control Study, Cancer Epidemiol Biomarkers Prev., 25, 282, 10.1158/1055-9965.EPI-15-0847

Malmer, 2003, Familial brain tumours—genetics or environment? A nationwide cohort study of cancer risk in spouses and first-degree relatives of brain tumour patients, Int. J. Cancer., 106, 260, 10.1002/ijc.11213

Wrensch, 1997, Familial and personal medical history of cancer and nervous system conditions among adults with glioma and controls, Am. J. Epidemiol., 145, 581, 10.1093/oxfordjournals.aje.a009154

Malmer, 1999, Familial aggregation of astrocytoma in northern Sweden: An epidemiological cohort study, Int. J. Cancer., 81, 366, 10.1002/(SICI)1097-0215(19990505)81:3<366::AID-IJC9>3.0.CO;2-0

Hill, 2003, Cancer in first-degree relatives and risk of glioma in adults, Cancer Epidemiol Biomarkers Prev., 12, 1443

Scheurer, 2007, Aggregation of cancer in first-degree relatives of patients with glioma, Cancer Epidemiol Biomarkers Prev., 16, 2491, 10.1158/1055-9965.EPI-07-0576

Claus, 2011, Family and personal medical history and risk of meningioma, J Neurosurg., 115, 1072, 10.3171/2011.6.JNS11129

Ostrom, 2014, The epidemiology of glioma in adults: a “state of the science” review, Neuro. Oncol., 16, 896, 10.1093/neuonc/nou087

Johnson, 2014, Childhood brain tumor epidemiology: a brain tumor epidemiology consortium review, Cancer Epidemiol Biomarkers Prev., 23, 2716, 10.1158/1055-9965.EPI-14-0207

Wiemels, 2010, Epidemiology and etiology of meningioma, J. Neurooncol., 99, 307, 10.1007/s11060-010-0386-3

Ostrom, 2019, Risk Factors For Childhood And Adult Primary Brain Tumors, Neuro. Oncol., 10.1093/neuonc/noz123

Scheie, 2019, Biomarkers in tumors of the central nervous system - a review, APMIS., 127, 265, 10.1111/apm.12916

Velazquez Vega, 2018, Incorporating Advances in Molecular Pathology Into Brain Tumor Diagnostics, Adv. Anat. Pathol., 25, 143, 10.1097/PAP.0000000000000186

Guerreiro Stucklin, 2018, Review of molecular classification and treatment implications of pediatric brain tumors, Curr. Opin. Pediatr., 30, 3, 10.1097/MOP.0000000000000562

Reifenberger, 2017, Advances in the molecular genetics of gliomas - implications for classification and therapy, Nat. Rev. Clin. Oncol., 14, 434, 10.1038/nrclinonc.2016.204

Cairncross, 1998, Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas, J. Natl. Cancer. Inst., 90, 1473, 10.1093/jnci/90.19.1473

Cairncross, 2013, Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402, J. Clin. Oncol., 31, 337, 10.1200/JCO.2012.43.2674

Vogelbaum, 2015, Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131, J. Neurooncol., 124, 413, 10.1007/s11060-015-1845-7

van den Bent, 2013, Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951, J. Clin. Oncol., 31, 344, 10.1200/JCO.2012.43.2229

Eckel-Passow, 2015, Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors, N. Engl. J. Med., 372, 2499, 10.1056/NEJMoa1407279

Yan, 2009, IDH1 and IDH2 mutations in gliomas, N Engl J Med., 360, 765, 10.1056/NEJMoa0808710

The Cancer Genome Atlas Research Network, 2015, Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas, N. Engl. J. Med., 372, 2481, 10.1056/NEJMoa1402121

Qi, 2014, Isocitrate dehydrogenase mutation is associated with tumor location and magnetic resonance imaging characteristics in astrocytic neoplasms, Oncol. Lett., 7, 1895, 10.3892/ol.2014.2013

Paldor, 2016, Frontal glioblastoma multiforme may be biologically distinct from non-frontal and multilobar tumors, J Clin Neurosci., 34, 128, 10.1016/j.jocn.2016.05.017

Ceccarelli, 2016, Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma, Cell., 164, 550, 10.1016/j.cell.2015.12.028

Hegi, 2005, MGMT gene silencing and benefit from temozolomide in glioblastoma, N. Engl. J. Med., 352, 997, 10.1056/NEJMoa043331

Hegi, 2008, Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity, J. Clin. Oncol., 26, 4189, 10.1200/JCO.2007.11.5964

Stupp, 2007, Chemoradiotherapy in malignant glioma: standard of care and future directions, J. Clin. Oncol., 25, 4127, 10.1200/JCO.2007.11.8554

Noushmehr, 2010, Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma, Cancer Cell., 17, 510, 10.1016/j.ccr.2010.03.017

van den Bent, 2013, MGMT-STP27 methylation status as predictive marker for response to PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951, Clin. Cancer Res., 19, 5513, 10.1158/1078-0432.CCR-13-1157

Kool, 2012, Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas, Acta Neuropathol., 123, 473, 10.1007/s00401-012-0958-8

Northcott, 2012, Molecular subgroups of medulloblastoma, Expert Rev. Neurother., 12, 871, 10.1586/ern.12.66

Northcott, 2012, Medulloblastomics: the end of the beginning, Nat. Rev. Cancer., 12, 818, 10.1038/nrc3410

Northcott, 2017, The whole-genome landscape of medulloblastoma subtypes, Nature., 547, 311, 10.1038/nature22973

Jones, 2014, Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma, Nat. Rev. Cancer., 14, 10.1038/nrc3811

Wu, 2014, The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma, Nat. Genet., 46, 444, 10.1038/ng.2938

Mackay, 2017, Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma, Cancer Cell, 32, 520, 10.1016/j.ccell.2017.08.017

Hoffman, 2016, Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma: implications for diagnostic biopsy and targeted therapeutics, Acta Neuropathol. Commun., 4, 1, 10.1186/s40478-015-0269-0

Grill, 2012, Critical oncogenic mutations in newly diagnosed pediatric diffuse intrinsic pontine glioma, Pediatr. Blood Cancer., 58, 489, 10.1002/pbc.24060

Lapin, 2017, Genomic Insights into Diffuse Intrinsic Pontine Glioma, Front. Oncol., 7, 57, 10.3389/fonc.2017.00057

Ostrom, 2016, Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004-2012, varying), J. Neurooncol, 130, 31, 10.1007/s11060-016-2217-7

Weir, 2014, Evaluation of North American Association of Central Cancer Registries’ (NAACCR) data for use in population-based cancer survival studies, Journal of the National Cancer Institute Monogr., 2014, 198, 10.1093/jncimonographs/lgu018

Wilson, 2014, Coding completeness and quality of relative survival-related variables in the National Program of Cancer Registries Cancer Surveillance System, 1995-2008, J Registry Manag, 41, 65

Kleihues, 1993, The new WHO classification of brain tumours, Brain Pathol., 3, 255, 10.1111/j.1750-3639.1993.tb00752.x

van den Bent, 2010, Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician’s perspective, Acta Neuropathol., 120, 297, 10.1007/s00401-010-0725-7

Aldape, 2000, Discrepancies in diagnoses of neuroepithelial neoplasms: the San Francisco Bay Area Adult Glioma Study, Cancer., 88, 2342, 10.1002/(SICI)1097-0142(20000515)88:10<2342::AID-CNCR19>3.0.CO;2-X

Sahm, 2014, Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma, Acta Neuropathol., 128, 551, 10.1007/s00401-014-1326-7

Kruchko, 2019, Cancer collection efforts in the United States provide clinically relevant data on all primary brain and other CNS tumors, Neurooncol Pract., 6, 330

Thông tin
Thông tin xuất bản

Neuro-Oncology

Tập 22 Số Supplement_1

iv1-iv96

Thông tin tác giả